General
Preferred name
TEZACITABINE
Synonyms
Anhydrous ()
FMDC ()
MDL 101,731 ()
TEZACITABINE ANHYDROUS ()
Tezacitabina ()
KW-2331 ()
MDL-101731 ()
FMD-C ()
Tezacitabine monohydrate ()
P&D ID
PD077537
CAS
130306-02-4
Tags
available
drug candidate
Drug indication
Adenocarcinoma
Gastric adenocarcinoma
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Tezacitabine is a cytostatic and cytotoxic antimetabolite and a nucleoside analogue. Tezacitabine irreversibly inhibits the ribonucleotide reductase and interferes with DNA replication and repair. Tezacitabine effectively induces cells apoptotic. Tezacitabine has the potential for leukemias and solid tumors (carcinomas) treatment[1][2].
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
4
ChEMBL Drugs
DrugBank
DrugMAP
MedChem Express Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
27
Molecular Weight
257.08
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-1.07
TPSA
110.6
Fraction CSP3
0.4
Chiral centers
3.0
Largest ring
6.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Apoptosis
DNA/RNA Synthesis
Nucleoside antimetabolite/analog
Pathway
Cell Cycle/DNA Damage
Source data
